Eesti - eesti - Ravimiamet

novartis baltics sia - deksametasoon+tobramütsiin - silmatilgad, suspensioon - 1mg+3mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

novartis baltics sia - deksametasoon - silmatilgad, suspensioon - 1mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

novartis baltics sia - moksifloksatsiin - silmatilgad, lahus - 5mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

novartis baltics sia - tobramütsiin - silmatilgad, lahus - 3mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

novartis baltics sia - tsiprofloksatsiin - silmatilgad, lahus - 3mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

novartis baltics sia - deksametasoon+neomütsiin+polümüksiin b - silmatilgad, suspensioon - 1mg+3500rÜ+6000rÜ 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

novartis baltics sia - ondansetroon - süste-/infusioonilahus - 2mg 1ml 2ml 5tk; 2mg 1ml 4ml 5tk

Eesti - eesti - Ravimiamet

novartis baltics sia - ondansetroon - õhukese polümeerikattega tablett - 8mg 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).